Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

By Pavel ME, Hainsworth JD, Baudin E et al.

Double-blind, placebo-controlled, registered NCT00412061